1. Developing Drugs to Neglected Tropical Diseases
Waldir Ventura Filho
IEEE Number:
President of IEEE CS UFABC Student Chapter
Santo André – São Paulo – Brazil

2. Neglected Tropical diseases
Group of parasitic and bacterial diseases
Affect more than 1.5 billion people worldwide
Related to poverty and lack of access to minimum health and sanitation
Affect physical and cognitive development
Examples: barber bug fever, ascariasis, elephantiasis, leishmaniasis

3. Drugs Overview
Drugs for NDT did not evolved as the same of heart diseases, which affects rich countries as well
The risk of investment would be high because of poor countries
Rigorous market analysis for new drugs because is related to the welfare of human beings
Accuracy needs to be high since it deals with lives
By the year 2010 more than half drugs introduced to the market was only na incremental innovation

4. Drugs Research
R&D for drugs consists of a long chain from basic research, pass through clinical analysis before the manufactuiring and launch
According to FDA, development of a new drug takes 10 to 15 years
Scientific community takes effort in researches
Limitation in the public’s purchasing power limitates the production

5. The solution Create a new business model
Integrate drug innovation research with producers
Contemplate the whole process
Development
Clinical Analysis
Production
Launch
Contemplate demand of NTD

6. Use The Open Intellectual Property Movement
How make it happen
Analysis of IEEE CS 2022 report
Understand the 23 technologies in 2022
Evaluation of technologies
Use The Open Intellectual Property Movement

7. The project Player 4 Player 1 Player 3 Player 2 Colaborative platform
Join forces of each part of the process
Four stages of the production
Four playerrs on the platform
Player 4
Player 1
Player 3
Player 2

8. Players Player 1: Research institutions
Responsible for creating a new molecule
Scientists, Universities Professors
Relationship with existing researches
Co-creating ideas
Player 2: Institutes of Clinical Analysis
Responsible for clinical analysis
Whole process of clinical analysis
Companies with know-how in the area

9. Players Player 3: Pharmaceutical Companies
Responsible for the production
Produce and launch the drug to the market
Companies able to produce on a large scale
Accredited Company
Player 4: Manager (may be the World Health Organization)
Manage the entire system
Integrate all the players
Follow and moderate the steps of the work

10. Platform Advantages Managed by WHO Selection of best players
Reduce time of production
Exclude the lack between the players
Integrated idea
Ease of communication
Co-creation

11. Image References
anoJqdIDJIE/Tocsna77ldI/AAAAAAAAALY/gZob2qvfRfM/s1600/Picture2.png